AstraZeneca PLC (AZN)

AI-powered earnings prediction for AstraZeneca PLC (AZN).

204.20
-2.12%
USD, 2 days ago
Market Cap
319.92B
Google

Company Overview

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple next-generation therapies for obesity and type 2 diabetes; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Sector
Healthcare
Industry
Drug Manufacturers - General
Phone
44 20 3749 5000
Headquarters
1 Francis Crick Avenue
Cambridge, CB2 0AA
United Kingdom

Key Metrics

P/E Ratio (TTM)
31.60
Forward P/E
34.81
Price to Book
6.58
Beta
0.19
Profit Margin
17.41%
Gross Margin
81.66%
Return on Equity
22.84%
Return on Assets
8.01%
Earnings Growth
54.70%
Revenue Growth
4.10%
Dividend Yield
154.00%
Dividend Rate
$3.21

Financial Health

Total Cash
$5.74B
Total Debt
$29.70B
Debt to Equity
60.97
Current Ratio
0.94
Free Cash Flow
$6.65B
Operating Cash Flow
$14.57B

Analyst Recommendations

Target Price (Mean)
$164.66
Target High
$232.00
Target Low
$98.00
Recommendation
buy
Analyst Coverage
9 Analysts

Trading Ideas

Related Stocks